Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man.
Identifieur interne : 001824 ( PubMed/Corpus ); précédent : 001823; suivant : 001825Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man.
Auteurs : R. Raisman-Vozari ; J A Girault ; S. Moussaoui ; C. Feuerstein ; P. Jenner ; C D Marsden ; Y. AgidSource :
- Brain research [ 0006-8993 ] ; 1990.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Animals, Callitrichinae, Corpus Striatum (metabolism), Corpus Striatum (physiopathology), Dopamine (metabolism), Dopamine (physiology), Dopamine and cAMP-Regulated Phosphoprotein 32, Female, Humans, Male, Nerve Tissue Proteins (metabolism), Parkinson Disease, Secondary (metabolism), Phosphoproteins, Phosphorylation, Rats, Substantia Nigra (physiology).
- MESH :
- chemical , metabolism : Dopamine, Nerve Tissue Proteins.
- metabolism : Corpus Striatum, Parkinson Disease, Secondary.
- chemical , physiology : Dopamine, Substantia Nigra.
- physiopathology : Corpus Striatum.
- Aged, Aged, 80 and over, Animals, Callitrichinae, Dopamine and cAMP-Regulated Phosphoprotein 32, Female, Humans, Male, Phosphoproteins, Phosphorylation, Rats.
Abstract
The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.
PubMed: 2105823
Links to Exploration step
pubmed:2105823Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man.</title>
<author><name sortKey="Raisman Vozari, R" sort="Raisman Vozari, R" uniqKey="Raisman Vozari R" first="R" last="Raisman-Vozari">R. Raisman-Vozari</name>
<affiliation><nlm:affiliation>INSERM U 289, CHU Pitié-Salpêtrière, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Girault, J A" sort="Girault, J A" uniqKey="Girault J" first="J A" last="Girault">J A Girault</name>
</author>
<author><name sortKey="Moussaoui, S" sort="Moussaoui, S" uniqKey="Moussaoui S" first="S" last="Moussaoui">S. Moussaoui</name>
</author>
<author><name sortKey="Feuerstein, C" sort="Feuerstein, C" uniqKey="Feuerstein C" first="C" last="Feuerstein">C. Feuerstein</name>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P" last="Jenner">P. Jenner</name>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C D" last="Marsden">C D Marsden</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:2105823</idno>
<idno type="pmid">2105823</idno>
<idno type="wicri:Area/PubMed/Corpus">001824</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001824</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man.</title>
<author><name sortKey="Raisman Vozari, R" sort="Raisman Vozari, R" uniqKey="Raisman Vozari R" first="R" last="Raisman-Vozari">R. Raisman-Vozari</name>
<affiliation><nlm:affiliation>INSERM U 289, CHU Pitié-Salpêtrière, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Girault, J A" sort="Girault, J A" uniqKey="Girault J" first="J A" last="Girault">J A Girault</name>
</author>
<author><name sortKey="Moussaoui, S" sort="Moussaoui, S" uniqKey="Moussaoui S" first="S" last="Moussaoui">S. Moussaoui</name>
</author>
<author><name sortKey="Feuerstein, C" sort="Feuerstein, C" uniqKey="Feuerstein C" first="C" last="Feuerstein">C. Feuerstein</name>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P" last="Jenner">P. Jenner</name>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C D" last="Marsden">C D Marsden</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name>
</author>
</analytic>
<series><title level="j">Brain research</title>
<idno type="ISSN">0006-8993</idno>
<imprint><date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Callitrichinae</term>
<term>Corpus Striatum (metabolism)</term>
<term>Corpus Striatum (physiopathology)</term>
<term>Dopamine (metabolism)</term>
<term>Dopamine (physiology)</term>
<term>Dopamine and cAMP-Regulated Phosphoprotein 32</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Nerve Tissue Proteins (metabolism)</term>
<term>Parkinson Disease, Secondary (metabolism)</term>
<term>Phosphoproteins</term>
<term>Phosphorylation</term>
<term>Rats</term>
<term>Substantia Nigra (physiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
<term>Nerve Tissue Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term>
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Dopamine</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Callitrichinae</term>
<term>Dopamine and cAMP-Regulated Phosphoprotein 32</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Phosphoproteins</term>
<term>Phosphorylation</term>
<term>Rats</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2105823</PMID>
<DateCreated><Year>1990</Year>
<Month>03</Month>
<Day>19</Day>
</DateCreated>
<DateCompleted><Year>1990</Year>
<Month>03</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8993</ISSN>
<JournalIssue CitedMedium="Print"><Volume>507</Volume>
<Issue>1</Issue>
<PubDate><Year>1990</Year>
<Month>Jan</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Brain research</Title>
<ISOAbbreviation>Brain Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man.</ArticleTitle>
<Pagination><MedlinePgn>45-50</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raisman-Vozari</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>INSERM U 289, CHU Pitié-Salpêtrière, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Girault</LastName>
<ForeName>J A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Moussaoui</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Feuerstein</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jenner</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Marsden</LastName>
<ForeName>C D</ForeName>
<Initials>CD</Initials>
</Author>
<Author ValidYN="Y"><LastName>Agid</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Brain Res</MedlineTA>
<NlmUniqueID>0045503</NlmUniqueID>
<ISSNLinking>0006-8993</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051937">Dopamine and cAMP-Regulated Phosphoprotein 32</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002143" MajorTopicYN="N">Callitrichinae</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051937" MajorTopicYN="N">Dopamine and cAMP-Regulated Phosphoprotein 32</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010750" MajorTopicYN="Y">Phosphoproteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year>
<Month>1</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1990</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1990</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">2105823</ArticleId>
<ArticleId IdType="pii">0006-8993(90)90520-L</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001824 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001824 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:2105823 |texte= Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:2105823" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |